Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.

Fragioudaki M, Tsirakis G, Pappa CA, Aristeidou I, Tsioutis C, Alegakis A, Kyriakou DS, Stathopoulos EN, Alexandrakis MG.

Leuk Res. 2012 Aug;36(8):1004-8. doi: 10.1016/j.leukres.2012.03.012. Epub 2012 Apr 10.

PMID:
22498341
2.

BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.

Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J.

Ann Hematol. 2014 Apr;93(4):635-44. doi: 10.1007/s00277-013-1924-9. Epub 2013 Oct 19.

3.

Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.

Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J.

Leuk Res. 2013 Sep;37(9):1089-93. doi: 10.1016/j.leukres.2013.05.014. Epub 2013 Jun 12.

PMID:
23768867
4.

B cell-activating factor: its clinical significance in multiple myeloma patients.

Fragioudaki M, Boula A, Tsirakis G, Psarakis F, Spanoudakis M, Papadakis IS, Pappa CA, Alexandrakis MG.

Ann Hematol. 2012 Sep;91(9):1413-8. doi: 10.1007/s00277-012-1470-x. Epub 2012 Apr 21.

PMID:
22526370
5.

Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.

Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.

Eur J Haematol. 2004 Apr;72(4):252-8.

PMID:
15089762
6.

Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.

Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG.

Cytokine. 2011 Dec;56(3):616-20. doi: 10.1016/j.cyto.2011.08.034. Epub 2011 Sep 21.

PMID:
21940178
7.

Circulating angiogenic cytokines in multiple myeloma and related disorders.

Urba ska-Rys H, Wierzbowska A, Robak T.

Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51.

8.

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM.

Haematologica. 2007 Aug;92(8):1075-82. Epub 2007 Jul 20.

9.

Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.

Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.

Ann Hematol. 2003 Jan;82(1):19-23. Epub 2002 Dec 18.

PMID:
12574959
10.

Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.

Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, Greipp PR, Lust JA, Rajkumar SV.

Br J Haematol. 2003 Oct;123(2):305-8.

PMID:
14531913
12.

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.

Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS.

Eur J Haematol. 2008 Sep;81(3):177-84. doi: 10.1111/j.1600-0609.2008.01099.x. Epub 2008 May 27.

PMID:
18510703
14.

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.

Cancer Res. 2006 Jul 1;66(13):6675-82.

15.

Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.

Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Gentile M, Morabito F, Ferrarini M.

Eur J Haematol. 2010 Oct;85(4):314-20. doi: 10.1111/j.1600-0609.2010.01482.x. Epub 2010 Jul 28.

PMID:
20546021
16.

Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma.

Pappa CA, Tsirakis G, Roussou P, Xekalou A, Goulidaki N, Konsolas I, Alexandrakis MG, Stathopoulos EN.

Leuk Res. 2013 Dec;37(12):1628-31. doi: 10.1016/j.leukres.2013.09.012. Epub 2013 Sep 21.

PMID:
24183234
17.

Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma.

Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB, Zannettino AC.

Clin Cancer Res. 2006 Dec 1;12(23):6973-7.

18.

Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.

Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R.

Leuk Lymphoma. 2011 Jul;52(7):1281-9. doi: 10.3109/10428194.2011.569695. Epub 2011 May 23.

PMID:
21599578
19.

Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.

Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE.

Ann Rheum Dis. 2009 Jun;68(6):836-43. doi: 10.1136/ard.2008.091405. Epub 2008 Jul 15.

PMID:
18628284
20.

Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.

Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.

Eur J Haematol. 2006 Jan;76(1):51-7.

PMID:
16343271

Supplemental Content

Support Center